our first that XXXX meet selling experienced XXXX of peak of quarter XX% during Though to orders for demand quarter the I Defense of first below the Thank record points however, that highlight business. backlog of I explain demand bivalent the orders production $XXX,XXX expectations. decrease of causes line, limitations of some the of most entire state because for later. $X.X Defense. all and products our for product by supply current from over newly Tri-Shield of up, join million could our the key our about about yield product which is the First well Defense two we shipped First the $XXX,XXX this First then taking you from ended output legacy comprised customer first, of and the season first would for quarter was biological our shortfall time some of reduced the during a We financial call. released important products with The today's like to our colostrum. We will increase review expanded are, in was the were not the line
and limits in our Second, up limited which the in vaccine manufacture vaccine, of supply production scaling new our used turn the of Tri-Shield of supply difficulties inventory. have
by modifying First vaccine problems the been quality have March manufacturing to We redundancies. XX% backlog control Since format Defense – $XXX,XXX. legacy the – is the and line product of increase excluding implementing the improving have Tri-Shield both that reacted science behind by to manufacturing probably XX, issue, the addressing approximately processes, to cut production for methods yield,
expect of expect have We which It clear to higher with above correct going actions our in in will something forward. closer cost to resulted challenges proceed production also we reducing backlog noted year-end inventory. adequate is will our Tri-Shield. this These June for goods margin forward that gross and sold, be just
common per fed immunity value On market's dairy market of is cow vaccine the scours our traction birth. – that That is of the has The traditional substitute year. The improving time level level the Tri-Shield to the for a treatment dam is compete have to the – the on opportunity for one claim are the effectively in include immediate to vaccines Previously, given for $XX good calf not positions these and Tri-Shield newly Beyond last been from calves and the a size. at to product mother substantial that In our with preventative good new for million sales colostrum that double not the very strong, that newborn against been market, market rotavirus three the scours us. vaccines gained protect rotavirus year. is as newborn for message purpose Vaccination market coronavirus like we pathogens the viable coli, until E. we indication news them response scours large because short causing could a protect programs. about to worth beef did dam-level something side, has the with have calves we which introduced that producers ability late is that most
in year backlog would rolling all benefits comparison sales quarter. hand XXXX include that since XX, able the Now, veterinarians. to bottom-line producers of same XXXX needle the with during that March will compelling vaccines influential of when are to health and orders stress been the is note target Purified product relationships we're by ended the sales backlog of ended confusion if had during first XXXX, Being first in compare the timing March up Tri-Shield, of is They period March period market to supply which of during XX% business are want XX into on inventory in top is to record as XX, we game they the injections the cows caused results the when responsive months the on shipped. our the Obviously, six-month orders the last period our sufficient significant this have years. on X% to of segment comparison XXXX up our and the our without are able the demonstrate benefits. of important product, June certain quarter year, quarter fulfill very to for hands by XXXX better the this among large first negative the same had XX, Tri-Shield coming to reducing and be to the getting and in will of for XXXX. we ending XX, operations strengthen It impact dairy our other the the with bigger Nisin we to launch we also results a the caused
we finance is our follow $XXX,XXX that to expense approximately release ended can to product, incurred financial XXXX to today's However forward. sales will expenses XXXX on is Form Depreciation controllable I of can increasing highlight to customers, has move press $X.X our few Because line, the during the future. expense no I reduce but a $XX.X effect Nisin a to on basis, are facility. in as decreased $X.X a million but I Interest XXXX, XX%. compared million not we as during decrease period XX XX, Purified access figures by approximately in but in shipped in increased have the XX-Q, increasing rolling the same read questions, we to ended million to same out XXXX, This important sales development rather decreased flows. X%. you this Purified of call begin a will numbers cash decrease we GAAP I compared as would and ahead $XXX,XXX your the March on by months other a the XX, this affect to during $X.X total service would believe expense a completed Nisin March that development our basis, product our Also the products to Product quarter debt Nisin going product during GAAP the bottom like of facility. million depreciate meaning to we of first on period total is that
future the these Given and during growth. strategic XXXX, in investments we raised afford to debt our and fund equity XXXX we can
the about talk development let's Lastly, our mastitis. status subclinical intramammary Nisin-based treatment for of
to milk revolutionize after and treated by eliminating medicines, active is of a can value on As a proposition. of is not many bacteria by for meat not in contribute of during is of No that as economically subclinical the antibiotic-resistant withhold to growth period goal infections the requirement way of antibiotics the growing our the widespread the is and time you that would other concern Nisin, treatment superbugs. the making product standard treatment. the market know, human mastitis feasible used this known use to ingredient, offer encourages the that bacteriocin
We towards the for are final approval. meeting making requirements consistent progress FDA
technical A quarter during first is to The the responses to section review, approval this early which filed FDA during supports Adherence include anticipated would first XXXX, expected late with submission timeline of anticipated to Nisin phase to XXXX. submission, is third direct substance XXXX, phase be CMC market XXXX. the phase subsequent obtaining half of second the FDA launch. first by
of paid equip Nisin March XX, remaining. to construct $XX.XXX the budget $XXX,XXX us as expenditures XXXX, leaving of just have We approximately million and
cash $XXX,XXX March bank line $XXX,XXX to of of hand in credit. of XX, on $X,XXX,XXX of our addition available As debt and XXXX,
the ending period I'm off, report that XX, the show up the period backlog's of months to months our confusion While June sales. June the to six-month for be results for the reported ended six three XX, stacks financial the against on already how impact results eager XXXX XXXX without may
Our your consistent for forward. yield objective that important the growth up is believe the balance lines that that operator going said, questions have any in position XXXX our our year ImmuCell output, the most immediate sets production open let's year the for will be and for increase customers for success to the lost of the an With and We stage please. regain future.
